Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2013

Open Access 01-12-2013 | Research article

Time from diagnosis to surgery and prostate cancer survival: a retrospective cohort study

Authors: Maria Theresa Redaniel, Richard M Martin, David Gillatt, Julia Wade, Mona Jeffreys

Published in: BMC Cancer | Issue 1/2013

Login to get access

Abstract

Background

A diagnosis of prostate cancer leads to emotional distress and anxiety, prompting calls for rapid diagnostic pathways. Nevertheless, it remains unclear what impact time between diagnosis and surgery has upon prostate cancer survival.

Methods

Using national databases for England (cancer registries, Hospital Episode Statistics and Office of National Statistics), we identified 17,043 men with prostate cancer, aged 15 years and older, diagnosed in 1996–2009, and who had surgical resection with curative intent within 6 months of diagnosis. We used relative survival to investigate associations between waiting times and five- and ten-year survival.

Results

Five- and ten-year relative survival estimates for the total study sample were 1.04 (95% CI: 1.04 to 1.05) and 1.08 (95% CI: 1.06-1.09), respectively. There were no notable differences in survival between patients who had surgery at 0–3 and 4–6 months after diagnosis. Relative survival was higher among the elderly (>65) and those with well and moderately differentiated tumours.

Conclusion

The high relative survival in our cohort probably reflects adherence to selection criteria for surgery among men with localised prostate cancer. Among men treated with surgery within 6 months of diagnosis, we found little evidence of an association between time from diagnosis to surgery and survival.
Literature
1.
Baker P, Beesley H, Dinwoodie R, Fletcher I, Ablett J, Holcombe C, Salmon P: You’re putting thoughts into my head’: a qualitative study of the readiness of patients with breast, lung or prostate cancer to address emotional needs through the first 18 months after diagnosis. Psychooncology. 2013, 22 (6): 1402-1410. 10.1002/pon.3156.CrossRefPubMed
2.
Brocken P, Prins JB, Dekhuijzen PN, van der Heijden HF: The faster the better?-A systematic review on distress in the diagnostic phase of suspected cancer, and the influence of rapid diagnostic pathways. Psychooncology. 2012, 21 (1): 1-10. 10.1002/pon.1929.CrossRefPubMed
3.
Bourgade V, Drouin SJ, Yates DR, Parra J, Bitker MO, Cussenot O, Roupret M: Impact of the length of time between diagnosis and surgical removal of urologic neoplasms on survival. World J Urol. 2013, [Epub ahead of print]
4.
Sun M, Abdollah F, Hansen J, Trinh QD, Bianchi M, Tian Z, Briganti A, Shariat SF, Montorsi F, Perrotte P, et al: Is a treatment delay in radical prostatectomy safe in individuals with low-risk prostate cancer?. J Sex Med. 2012, 9 (11): 2961-2969. 10.1111/j.1743-6109.2012.02806.x.CrossRefPubMed
5.
van den Bergh RC, Albertsen PC, Bangma CH, Freedland SJ, Graefen M, Vickers A, van der Poel HG: Timing of curative treatment for prostate cancer: a systematic review. Eur Urol. 2013, 64 (2): 204-215. 10.1016/j.eururo.2013.02.024.CrossRefPubMedPubMedCentral
6.
Department of Health: The NHS cancer plan. 2000, London: Department of Health
7.
Department of Health: Cancer reform strategy. 2007, London: Department of Health
8.
Department of Health: Review of cancer waiting times standards. 2011, London: Department of Health
9.
National Institute for Health and Clinical Excellence: Prostate cancer: diagnosis and treatment. 2008, London: National Institute for Health and Clinical Excellence
10.
National Cancer Intelligence Network: Major surgical resections, England, 2004–2006. 2011, London: National Cancer Intelligence Network
11.
Maringe C, Mangtani P, Rachet B, Leon DA, Coleman MP, Dos Santos SI: Cancer incidence in South Asian migrants to England, 1986–2004: unraveling ethnic from socioeconomic differentials. Int J Cancer. 2013, 132 (8): 1886-1894. 10.1002/ijc.27826.CrossRefPubMed
12.
Shafique K, Morrison DS: Socio-economic inequalities in survival of patients with prostate cancer: role of age and Gleason grade at diagnosis. PloS One. 2013, 8 (2): e56184-10.1371/journal.pone.0056184.CrossRefPubMedPubMedCentral
13.
European Network of Cancer Registries: ENCR Definitions for the coding of basis of diagnosis. 1997, Lyon, France: European Network of Cancer Registries
14.
Department of Health: A practical guide to ethnic monitoring in the NHS and social care. 2005, London: Health Do
15.
Hospital Episode Statistics: How good is HES ethnic coding and where do the problems lie?. 2009, London: Hospital Episode Statistics
16.
Noble M, McLennan D, Wilkinson K, Whitworth A, Barnes H, Dibben C: The english indices of deprivation 2007. 2008, London: Department for Communities and Local Government
17.
Communities and Local Government: Using the english indices of deprivation 2007. 2007, London: Guidance
18.
Nur U, Shack LG, Rachet B, Carpenter JR, Coleman MP: Modelling relative survival in the presence of incomplete data: a tutorial. Int J Epidemiol. 2010, 39 (1): 118-128. 10.1093/ije/dyp309.CrossRefPubMed
19.
Royston P: Multiple imputation of missing values: update of ice. Stata J. 2005, 5: 527-536.
20.
Sterne JA, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, Wood AM, Carpenter JR: Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ. 2009, 338: b2393-10.1136/bmj.b2393.CrossRefPubMedPubMedCentral
21.
Brenner H, Gefeller O, Hakulinen T: Period analysis for ’up-to-date’ cancer survival data: theory, empirical evaluation, computational realisation and applications. Eur J Cancer. 2004, 40 (3): 326-335. 10.1016/j.ejca.2003.10.013.CrossRefPubMed
22.
StataCorp: Stata Statistical Software: Release 12. 2011, College Station, TX: StataCorp LP
23.
Ederer F, Axtell LM, Cutler SJ: The relative survival rate: a statistical methodology. Natl Cancer Inst Monogr. 1961, 6: 101-121.PubMed
24.
25.
Abern MR, Aronson WJ, Terris MK, Kane CJ, Presti JC, Amling CL, Freedland SJ: Delayed radical prostatectomy for intermediate-risk prostate cancer is associated with biochemical recurrence: possible implications for active surveillance from the SEARCH database. Prostate. 2013, 73 (4): 409-417. 10.1002/pros.22582.CrossRefPubMed
26.
O’Brien D, Loeb S, Carvalhal GF, McGuire BB, Kan D, Hofer MD, Casey JT, Helfand BT, Catalona WJ: Delay of surgery in men with low risk prostate cancer. J Urol. 2011, 185 (6): 2143-2147. 10.1016/j.juro.2011.02.009.CrossRefPubMed
27.
Bill-Axelson A, Holmberg L, Ruutu M, Haggman M, Andersson SO, Bratell S, Spangberg A, Busch C, Nordling S, Garmo H, et al: Radical prostatectomy versus watchful waiting in early prostate cancer. New Engl J Med. 2005, 352 (19): 1977-1984. 10.1056/NEJMoa043739.CrossRefPubMed
28.
Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, Gingrich JR, Wei JT, Gilhooly P, Grob BM, et al: Radical prostatectomy versus observation for localized prostate cancer. New Engl J Med. 2012, 367 (3): 203-213. 10.1056/NEJMoa1113162.CrossRefPubMedPubMedCentral
29.
Brimo F, Montironi R, Egevad L, Erbersdobler A, Lin DW, Nelson JB, Rubin MA, van der Kwast T, Amin M, Epstein JI: Contemporary grading for prostate cancer: implications for patient care. Eur Urol. 2012, 63 (5): 892-901.CrossRefPubMed
30.
Metadata
Title
Time from diagnosis to surgery and prostate cancer survival: a retrospective cohort study
Authors
Maria Theresa Redaniel
Richard M Martin
David Gillatt
Julia Wade
Mona Jeffreys
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2013
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-13-559

Other articles of this Issue 1/2013

BMC Cancer 1/2013 Go to the issue

Case report

TP53p.R337H is a conditional cancer-predisposing mutation: further evidence from a homozygous patient

Research article

Patient self-appraisal of change and minimal clinically important difference on the European organization for the research and treatment of cancer quality of life questionnaire core 30 before and during cancer therapy

Research article

MiR-204 down regulates SIRT1 and reverts SIRT1-induced epithelial-mesenchymal transition, anoikis resistance and invasion in gastric cancer cells

Research article

Assessment of HER2 status in breast cancer: overall positivity rate and accuracy by fluorescence in situ hybridization and immunohistochemistry in a single institution over 12 years: a quality control study

Study protocol

Effects of recreational soccer in men with prostate cancer undergoing androgen deprivation therapy: study protocol for the ‘FC Prostate’ randomized controlled trial

Research article

Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits